EP
BCRX icon

Eudaimonia Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Eudaimonia Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,000
Closed -$92K – 463
2021
Q1 		$92K Sell
9,000
-13,000
-59% -$134K 0.02% 493
2020
Q4 		$164K Sell
22,000
-58,600
-73% -$302K 0.04% 345
2020
Q3 		$277K Buy
+80,600
New +$345K 0.07% 242

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Eudaimonia Partners's BCRX Position: Q2 2021 in Review

Eudaimonia Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 9,000 shares — an estimated $92K sold.

Eudaimonia Partners first reported a position in BCRX in Q3 2020 and held it in 3 quarters. The position peaked at $277K in Q3 2020. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • Eudaimonia Partners reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 9,000 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $92K.
  • Eudaimonia Partners first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Eudaimonia Partners's BioCryst Pharmaceuticals position peaked at $277K in Q3 2020.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.